Glenmark Pharmaceuticals Ltd (GLENMARK)
₹1023.95▲2.43%
Glenmark Pharmaceuticals Ltd share Performance
- ₹997.4₹1027.25₹1023.95
2.59%
Low
Day's Volatility:2.92%
High
0.32%
- ₹561.1₹1098₹1023.95
45.20%
Low
52 Weeks Volatility:52.43%
High
7.23%
| Returns % | |
| 1 Month Return | -4.19 % |
| 3 Month Return | 20.24 % |
| 1 Year Return | 75.39 % |
| Market Stats | |
| Previous Close | ₹999.65 |
| Open | ₹1,002.85 |
| Volume | 4.21L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹28,208.94Cr |
Analyst Rating
based on 14 analysts
Based on 14 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹962.79
Source: S&P Global Market Intelligence
Company Information
Share Price: ₹1023.95 per share as on 10 May, 2024 04:01 PM
Market Capitalisation: ₹28,208.94Cr as of today
Revenue: ₹2,460.29Cr as on December 2023 (Q4 23)
Net Profit: ₹-330.82Cr as on December 2023 (Q4 23)
Listing date: 10 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Potentially Overvalued - 08 May, 2024
Based on a 2 Stage Free Cash Flow to Equity analysis, Glenmark Pharmaceuticals is estimated to be 34% overvalued with a fair value of ₹759. The company appears potentially overvalued at the current share price of ₹1.0k.
Glenmark Pharma Receives USFDA Approval for Edaravone Injection - 07 May, 2024
Glenmark Pharmaceuticals has received USFDA approval for its Edaravone injection, which is therapeutically and bioequivalent to the reference-listed drug Radicava injection. The company plans to launch the product via its marketing partner during fiscal year 2025. Gland Pharma reported about USD 19 million in sales in the US for the year ending January 2024.
Glenmark Recalls Blood Pressure Drug in US Market - 05 May, 2024
Glenmark Pharmaceuticals has recalled 3,264 bottles of Diltiazem Hydrochloride extended-release capsules from the US market due to failed dissolution specifications. The drug is used to treat high blood pressure.
Glenmark Pharma Receives FDA Approval for Acetaminophen and Ibuprofen Tablets - 03 May, 2024
Glenmark Pharmaceuticals has received final approval from the US FDA for its Acetaminophen and Ibuprofen Tablets, which are bioequivalent to Advil Dual Action with Acetaminophen Tablets. The market achieved annual sales of approximately $84.1 million.
Glenmark Pharma Gets USFDA Approval for New Drug - 29 Apr, 2024
Glenmark Pharmaceuticals has received final approval from the US FDA for its Acetaminophen and Ibuprofen tablets, which will be distributed in the US by Glenmark Therapeutics Inc. The new drug is used to relieve minor pains such as headaches, backaches, toothaches, menstrual cramps, muscle aches or arthritis pain. Shares of Glenmark Pharma gained more than 1% on the news.
Delhi High Court Restrains Glenmark from Selling Asthma Drug - 17 Apr, 2024
The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet. The court ruled that the mark is identical or deceptively similar to Sun Pharma Laboratories' registered mark for its anti-diabetes drug Istamet XR CP.
Glenmark Recalls High Blood Pressure Medication in US Market - 15 Apr, 2024
Glenmark Pharmaceuticals' US subsidiary is recalling a batch of Diltiazem Hydrochloride extended-release capsules used to treat high blood pressure in the American market. The recall was initiated after an Out of Specification (OOS) result was observed during a dissolution test at the 12-month mark in a long-term stability study.
Glenmark Pharma Recalls Medication in US Market - 14 Apr, 2024
Glenmark Pharmaceuticals is recalling a specific lot of Diltiazem Hydrochloride extended-release capsules used for high blood pressure treatment from the American market due to failed dissolution specifications. The affected lot has been produced in India and is being recalled by Glenmark Pharmaceuticals Inc., based in New Jersey.
Glenmark Pharmaceuticals Recalls Diltiazem Hydrochloride Capsules - 10 Apr, 2024
Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydrochloride extended-release capsules in the US market due to failed dissolution specifications. The drug is used to treat high blood pressure.
Glenmark Recalls Blood Pressure Medication - 09 Apr, 2024
Glenmark Pharmaceuticals has recalled 6,528 bottles of Diltiazem Hydrochloride capsules used in the treatment of high blood pressure due to failed dissolution specifications. The Class II recall was initiated on March 26.
Fundamentals of Glenmark Pharmaceuticals Ltd
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 8.59% to 10.55% in Mar 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, GLENMARK stock has moved up by 20.2%
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 114.1% return, outperforming this stock by 54.2%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.69% to 18.58% in Mar 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 3.32K Cr → 2.67K Cr (in ₹), with an average decrease of 19.7% per quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.65% to 46.64% in Mar 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 149.93 Cr → -351.37 Cr (in ₹), with an average decrease of 241.7% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 23.71% to 21.38% in Mar 2024 quarter
Glenmark Pharmaceuticals Ltd Valuation
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Today (-39.64x)
May 9, 2024
Industry (61.71x)
May 9, 2024
Highest (95.94x)
September 14, 2023
Mutual Fund Holdings
Shareholding Pattern
| Investors | Holdings % | Prev. 1 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.64% | 0.00 | |
| Foreign Institutions | 21.38% | 0.00 | |
| Mutual Funds | 10.55% | 0.00 | |
| Retail Investors | 18.58% | 0.00 | |
| Others | 2.85% | 0.00 |
Technicals of Glenmark Pharmaceuticals Ltd share
News & Events of Glenmark Pharmaceuticals Ltd
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Glenmark Pharmaceuticals Ltd shares.
Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1023.95
Glenmark Pharmaceuticals Ltd is listed on NSE
Glenmark Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1027.25.
- Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹997.4.
PE Ratio of Glenmark Pharmaceuticals Ltd is -39.64
PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 4.21L.
Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹28208.94Cr.
| Glenmark Pharmaceuticals Ltd(GLENMARK | Price |
|---|---|
52 Week High | ₹1098 |
52 Week Low | ₹561.1 |
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1023.95. It is down -6.74% from its 52 Week High price of ₹1098
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1023.95. It is up 82.49% from its 52 Week Low price of ₹561.1
| Glenmark Pharmaceuticals Ltd(GLENMARK | Returns |
|---|---|
1 Day Returns | 24.3% |
1 Month Returns | -4.19% |
3 Month Returns | 20.24% |
1 Year Returns | 75.39% |